This preclinical study in mouse models of multiple sclerosis found that intranasal administration of an antisense oligonucleotide targeting the RNA-binding protein HuR attenuated pain hypersensitivity and improved myelin restoration. The mechanism involved either promoting neuroprotection via HuD in a chronic model or suppressing microglial neuroinflammation in a relapsing-remitting model.